ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?

摘要

The recent outbreak of corona virus disease 2019(COVID-19), caused by a new virus, has spread to most countries around the world, which is now a global pandemic and public threat.[1, 2] Although COVID-19 has been controlled in China, the number of new infections is still rapidly increasing in many countries and leads to a high mortality. Some studies have found that old age, as well as the comorbidities, including hypertension, diabetes mellitus, and other cardiovascular diseases, lead to a high mortality rates after infection. [3, 4] COVID-19 belongs to the same family as viruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).[5, 6] Generally, although the onset of patients who infected with COVID-19 is not as dangerous as those infected with SARS, and the symptoms are even mild, the disease will accelerate suddenly in the later stage after infection, even leading to multiple organ failure, which may be related to the initiation of inflammatory storm induced by imbalance of the immune response.[7]